Maravai Lifesciences Holdings (MRVI) Accounts Payables (2020 - 2026)

Maravai Lifesciences Holdings' Accounts Payables history runs 7 years deep, the most recent figure standing at $8.5 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 10.39% year-over-year to $8.5 million in Q1 2026; TTM through Mar 2026 was $8.5 million, a 10.39% decrease from a year earlier, with the FY2025 full-year figure at $2.9 million, down 75.66% from the prior year.
• Accounts Payables climbed to $8.5 million in Q1 2026 per MRVI's latest filing, from $2.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $678.4 million in Q3 2023 and bottomed at $2.9 million in Q4 2025.
• The 5-year median for Accounts Payables is $10.0 million (2022), against an average of $94.7 million.
• Across the five-year window, Accounts Payables jumped 7072.01% in 2023 and tumbled 98.12% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $42.3 million in 2022, then plunged by 83.27% to $7.1 million in 2023, then jumped by 69.15% to $12.0 million in 2024, then plunged by 75.66% to $2.9 million in 2025, then soared by 193.3% to $8.5 million in 2026.
• Per Business Quant, the three latest MRVI Accounts Payables figures stand at $8.5 million (Q1 2026), $2.9 million (Q4 2025), and $8.0 million (Q3 2025).